Clinical Trial Update: Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating eplerenone for reducing target organ damage in patients with resistant arterial hypertension has completed. The update summarizes the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• eplerenone (eplerenone)

Snippet

Sponsor: University of Erlangen-Nürnberg Medical School | Conditions: Essential Hypertension | Phase 3 | Status: COMPLETED